title: Safe handling and administration of MABS: the guidance.
abstract: While monoclonal antibodies (MABs) are not as hazardous as cytotoxic drugs, there is concern among health professionals about the potential risks and the limited evidence about this. Guidance on the safe use of MABs is mainly to be found in national documents covering all systemic anti-cancer therapies, with the only consensus guidelines specifically on MABs coming from Australia. This article therefore summarises the existing guidance relating to MABs.
authors.forename: Donna
authors.initials: D
authors.lastname: McGowan
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001315:Australia; D016503:Drug Delivery Systems / Q000592:standards*; D006282:Health Personnel; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016273:Occupational Exposure / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents